Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Over a 12-month treatment period, patients on deferiprone demonstrated decreased blood ferritin and hippocampal QSM but caused accelerated cognitive decline and increased regional brain atrophy.

Negative Effect of Deferiprone Points to Impact of Iron Lowering in Alzheimer Disease

The findings suggest that future phase 3 trials should explore the duration of pain relief and headache recurrence, with the goal of developing structured treatment guidelines for PTH.

Sumatriptan Demonstrates Therapeutic Potential in Post-Traumatic Headache in Phase 2 Pilot Study

The phase 2 DIMENSION study results showed that SAGE-71 was well-tolerated but did not meet its primary end point, leading to Sage Therapeutics’ decision to discontinue its development.

Huntington Agent SAGE-718 to be Discontinued Following Disappointing Phase 2 DIMENSION Trial Results

At week 10, investigators observed no differences between triheptanoin and placebo on the frequency of movement disorder events in patients with Glut1 deficiency disorder.

Triheptanoin Shows No Significant Effect on Movement Disorder Events in Glut1 Deficiency Syndrome

Dean and chief academic officer at the University of Miami Miller School of Medicine.

Videos

The dean and chief academic officer at the University of Miami Miller School of Medicine discussed the university’s investment in computational biology to advance aging and neuroscience research. [WATCH TIME: 5 minutes]

Driving Innovation in Aging and Neurodegenerative Research: Henri Ford, MD, MHA 

Here's the latest multidisciplinary multiple sclerosis (MS) research from the International Journal of MS Care.

Research from IJMSC September 2024

William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology; Chair, Neurology; Neurologist-in-Chief, Yale New Haven Hospital

The William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine talked about the ongoing evolution of multiple sclerosis diagnostic criteria and the importance of comprehensive testing to guide early intervention and improve outcomes. [WATCH TIME: 5 minutes]

Evolution of Multiple Sclerosis Diagnostic Criteria and the Role of Spinal Taps: David A. Hafler, MD, FANA

, has been with the team since October 2019. Follow him on Twitter 

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Lara Jehi, MD, MHCDS. [LISTEN TIME: 20 minutes]

Episode 128: Machine Learning Algorithms to Predict Seizure Control in Epilepsy Surgery

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AANEM 2024

CTAD 2024

MDS 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Managing Neurofibromatosis Type 1 Related Plexiform Neurofibroma in Patients of Different Ages

An in-depth view into treatment and management of type 1 related plexiform neurofibroma across varying patient age ranges is provided by Kaleb Yohay, MD, of NYU Langone Health.

Kaleb Yohay, MD, introduces an upcoming Insights series dissecting care for a range of patient ages diagnosed with neurofibromatosis type 1 related plexiform neurofibroma.

UPCOMING SERIES: Managing Neurofibromatosis Type 1 Related Plexiform Neurofibroma in Patients of Different Ages

A key opinion leader offers a comprehensive overview of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), detailing its symptoms, clinical manifestations, prevalence, and impact on patients' quality of life.

Treatment Options and Management of Neurofibromatosis Type 1 Related Plexiform Neurofibroma

A neurofibromatosis specialist explores the complexities encountered in managing NF1-PN, highlighting the distinct challenges that arise when treating patients across different age groups.

Challenges When Managing Neurofibromatosis Type 1 Related Plexiform Neurofibroma

An expert in NF1-PN describes their approach to treatment decision-making for adolescents versus adults, and identifies key barriers and unmet needs in the transition from adolescent to adult care for patients with this condition.

Transition of Care for Neurofibromatosis Type 1 Related Plexiform Neurofibroma from Adolescent to Adulthood 

A healthcare expert examines Mirdametinib as an investigational treatment for NF1-PN, focusing on its potential role in managing the condition in adolescents and adults who have moved beyond pediatric care.

Current and Emerging Treatment Options for Neurofibromatosis Type 1 Related Plexiform Neurofibroma

Kaleb Yohay, MD, an expert in NF1-PN, emphasizes the importance of multidisciplinary and comprehensive team care in managing the condition, detailing the essential team members required to facilitate a successful transition from adolescent to adult care.

Importance of Multidisciplinary Care in Management of Neurofibromatosis Type 1 Related Plexiform Neurofibroma 

Lasso - DMD Peers and Perspectives NSP-21-NRD0157

 video series brings together pairs of expert clinicians and physicians to independently provide their insights on the latest and most up-to-date clinical care for specific neurologic diseases and disorders.

EP: 1.UPCOMING SERIES: Managing Neurofibromatosis Type 1 Related Plexiform Neurofibroma in Patients of Different Ages

EP: 2.Treatment Options and Management of Neurofibromatosis Type 1 Related Plexiform Neurofibroma

EP: 3.Challenges When Managing Neurofibromatosis Type 1 Related Plexiform Neurofibroma

EP: 4.Transition of Care for Neurofibromatosis Type 1 Related Plexiform Neurofibroma from Adolescent to Adulthood

EP: 5.Current and Emerging Treatment Options for Neurofibromatosis Type 1 Related Plexiform Neurofibroma

EP: 6.Importance of Multidisciplinary Care in Management of Neurofibromatosis Type 1 Related Plexiform Neurofibroma